Manning M, Stoev S, Kolodziejczyk A, Klis W A, Kruszynski M, Misicka A, Olma A, Wo N C, Sawyer W H
Department of Biochemistry, Medical College of Ohio, Toledo 43699-0008.
J Med Chem. 1990 Nov;33(11):3079-86. doi: 10.1021/jm00173a027.
We report the solid-phase synthesis of 21 linear analogues of A and D, two nonselective antagonists of the vasopressor (V1) and antidiuretic (V2) responses to arginine vasopressin (AVP). A is Aaa-D-Tyr(Et)-Phe-Val-Asn-Abu-Pro-Arg-Arg-NH2 (where Aaa = adamantylacetyl at position 1). D is the des-Arg9 analogue of A. Nine new analogues of A (1-9) and 12 new analogues of D (10-21) were obtained. The following substitutions either alone or in combination were incorporated in A and/or in D: phenylacetic acid (Phaa) and tert-butylacetic acid (t-Baa) at position 1; D-Tyr2, D-Tyr(Me)2; Gln4; Arg6, Lys6, Orn6, MeAla7. The nine new analogues of A are (1) [Arg6], (2) [Lys6], (3) [Orn6], (4) [Phaa1,Lys6], (5) [Phaa1,Orn6], (6) [D-Tyr2], (7) [D-Tyr2,Arg6], (8) [Phaa1,D-Tyr2], (9) [Phaa1,D-Tyr2,Arg6]. The 12 new analogues of D are (10) [Arg6], (11) [Lys6], (12) [Orn6], (13) [Phaa1,Lys6], (14) [Phaa1,Gln4,Lys6], (15) [Phaa,D-Tyr(Me)2,Lys6], (16) [Phaa,D-Tyr(Me)2,Gln4,Lys6], (17) [Phaa1,D-Tyr2,Gln4,Lys6], (18) [t-Baa1,Lys6], (19) [t-Baa1,Gln4,Lys6], (20) [Arg6,MeAla7], (21) [t-Baa1,Arg6,MeAla7]. All 21 peptides were examined for agonistic and antagonistic potencies in AVP V2 and V1 assays in rats. With the exception of 6, the eight remaining new analogues of A are equipotent or more potent than A as V1 antagonists. Peptides 2-9 are less potent than A as V2 antagonists. Three, 4, 5, and 9, exhibit significant gains in anti-V1/anti-V2 selectivities (selectivity ratio = 41, 14, and infinite, respectively), compared to A (anti-V1, pA2 = 7.75 +/- 0.07; selectivity ratio = 0.44). Peptide 9 is unique in both series. It is a highly potent V1 antagonist (anti-V1 pA2 = 8.62 +/- 0.11 and is the first linear peptide to exhibit substantial antidiuretic agonism (4.1 +/- 0.2 units/mg). With the exception of 12, the remaining 11 analogues of D are 8-40 times more potent than D as V1 antagonists. Eight of these peptides exhibit significant gains in anti-V1/anti-V2 selectivities compared to D (anti-V1 pA2 = 7.43 +/- 0.06; selectivity ratio = 1.6).(ABSTRACT TRUNCATED AT 400 WORDS)
我们报道了血管加压素(AVP)的血管收缩(V1)和抗利尿(V2)反应的两种非选择性拮抗剂A和D的21种线性类似物的固相合成。A为Aaa-D-Tyr(Et)-Phe-Val-Asn-Abu-Pro-Arg-Arg-NH2(其中Aaa为第1位的金刚烷乙酰基)。D为A的去-Arg9类似物。获得了9种新的A类似物(1 - 9)和12种新的D类似物(10 - 21)。在A和/或D中单独或组合引入了以下取代基:第1位的苯乙酸(Phaa)和叔丁基乙酸(t-Baa);D-Tyr2、D-Tyr(Me)2;Gln4;Arg6、Lys6、Orn6、MeAla7。9种新的A类似物为(1)[Arg6],(2)[Lys6],(3)[Orn6],(4)[Phaa1,Lys6],(5)[Phaa1,Orn6],(6)[D-Tyr2],(7)[D-Tyr2,Arg6],(8)[Phaa1,D-Tyr2],(9)[Phaa1,D-Tyr2,Arg6]。12种新的D类似物为(10)[Arg6],(11)[Lys6],(12)[Orn6],(13)[Phaa1,Lys6],(14)[Phaa1,Gln4,Lys6],(15)[Phaa,D-Tyr(Me)2,Lys6],(16)[Phaa,D-Tyr(Me)2,Gln4,Lys6],(17)[Phaa1,D-Tyr2,Gln4,Lys6],(18)[t-Baa1,Lys6],(19)[t-Baa1,Gln4,Lys6],(20)[Arg6,MeAla7],(21)[t-Baa1,Arg6,MeAla7]。在大鼠的AVP V2和V1测定中检测了所有21种肽的激动和拮抗效力。除6之外,A的其余8种新类似物作为V1拮抗剂与A等效或更强效。肽2 - 9作为V2拮抗剂比A效力更低。与A相比(抗V1,pA2 = 7.75 ± 0.07;选择性比率 = 0.44),3、4、5和9在抗V1/抗V2选择性方面有显著提高(选择性比率分别为41、14和无穷大)。肽9在两个系列中都是独特的。它是一种高效的V1拮抗剂(抗V1 pA2 = 8.62 ± 0.11),并且是第一种表现出显著抗利尿激动作用的线性肽(4.1 ± 0.2单位/毫克)。除12之外,D的其余11种类似物作为V1拮抗剂比D强8 - 40倍。与D相比(抗V1 pA2 = 7.43 ± 0.06;选择性比率 = 1.6),其中8种肽在抗V1/抗V2选择性方面有显著提高。(摘要截短于400字)